D. Boral Capital Reiterates Buy Rating for UroGen Pharma (NASDAQ:URGN)

UroGen Pharma (NASDAQ:URGN)‘s stock had its “buy” rating reaffirmed by research analysts at D. Boral Capital in a research note issued to investors on Wednesday,Benzinga reports. They currently have a $25.00 price objective on the stock. D. Boral Capital’s price target suggests a potential upside of 132.99% from the stock’s current price.

URGN has been the topic of a number of other research reports. EF Hutton Acquisition Co. I upgraded UroGen Pharma to a “strong-buy” rating in a research report on Monday, October 14th. HC Wainwright reiterated a “buy” rating and set a $60.00 target price on shares of UroGen Pharma in a research report on Tuesday, October 15th. Finally, Oppenheimer reissued an “outperform” rating and issued a $40.00 price target on shares of UroGen Pharma in a report on Wednesday, October 16th. Five investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $43.70.

UroGen Pharma Stock Performance

URGN stock traded up $0.80 during trading on Wednesday, hitting $10.73. 128,287 shares of the company traded hands, compared to its average volume of 442,661. UroGen Pharma has a 1 year low of $9.78 and a 1 year high of $20.70. The company has a market cap of $251.66 million, a PE ratio of -3.41 and a beta of 1.09. The stock’s 50-day simple moving average is $11.50 and its 200 day simple moving average is $13.21. The company has a debt-to-equity ratio of 4.77, a current ratio of 9.00 and a quick ratio of 8.77.

UroGen Pharma (NASDAQ:URGN) last posted its earnings results on Wednesday, November 6th. The company reported ($0.55) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.84) by $0.29. The firm had revenue of $25.20 million during the quarter, compared to analyst estimates of $24.22 million. During the same quarter in the prior year, the firm earned ($0.68) earnings per share. On average, equities analysts expect that UroGen Pharma will post -3.1 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. grew its holdings in shares of UroGen Pharma by 90.9% during the third quarter. China Universal Asset Management Co. Ltd. now owns 8,100 shares of the company’s stock worth $103,000 after buying an additional 3,856 shares in the last quarter. BNP Paribas Financial Markets boosted its position in UroGen Pharma by 221.8% during the third quarter. BNP Paribas Financial Markets now owns 8,546 shares of the company’s stock worth $109,000 after acquiring an additional 5,890 shares during the last quarter. Intech Investment Management LLC purchased a new stake in UroGen Pharma during the 3rd quarter valued at about $155,000. Verition Fund Management LLC acquired a new stake in UroGen Pharma in the 3rd quarter valued at about $168,000. Finally, SG Americas Securities LLC purchased a new position in UroGen Pharma in the 3rd quarter worth approximately $179,000. 91.29% of the stock is owned by institutional investors and hedge funds.

About UroGen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.